Search

Strategies for managing neovascular AMD and DMO in routine clinical care

Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

A paradigm shift in the way we approach cataract surgery

Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Quality matters in the management of serious eye disorders

The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

Amnion-assisted conjunctival epithelial redirection (ACER): Enhancing stem cell transplantation treatment of total limbal stem cell deficiency

An exploration of Professor Harminder Dua’s recent work using a technique called amnion-assisted conjunctival epithelial redirection (ACER) to aid the success of conjunctival-limbal grafting procedures. ACER provides a refined way to use amniotic membrane (amnion), such as Omnigen® (NuVision® Biotherapies,...

Stem cell transplantation and pterygium surgery

Pterygium is a benign, fibrovascular overgrowth of bulbar conjunctiva extending onto the cornea and has been associated with ultraviolet (UV) light exposure. The prevalence of pterygium worldwide varies between geographical zones but has been reported to range between three and...

Herpes zoster ophthalmicus: a clinician’s perspective

Introduction Herpes zoster, commonly known as shingles, is caused by the reactivation of varicella zoster virus (VZV). The term herpes is derived from a Greek work, herpein, which means ‘creeping’ and the word zoster means a belt or a girdle...